MIT Holding, Inc. (MITD) Partnership Commences Treatment of Patients in Phase 3 FDA Clinical Trial With SERRG
MIT Holding today reported the intake of patients for a U.S. FDA clinical trial. MIT Holding, through its affiliates, is acting as sub-investigators for Melinta Theraputics, the primary investigator in the study managed by SERRG Savannah. MIT Holding will generate revenues throughout this 12-month study. Walter Drakeford, president of MIT Holding stated, "We are pleased to open this new revenue stream as a result of being selected by SERRG as a sub-investigator facility. This is evidence that our corporate re-organization and business model is capable of opening and generating new income streams through our partner affiliation programs. The facility and…